wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q34180815-9BD19F22-20F2-4CE7-9203-72B295AD7535
Q34180815-9BD19F22-20F2-4CE7-9203-72B295AD7535
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34180815-9BD19F22-20F2-4CE7-9203-72B295AD7535
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
P2860
Q34180815-9BD19F22-20F2-4CE7-9203-72B295AD7535
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34180815-9BD19F22-20F2-4CE7-9203-72B295AD7535
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
69f22748e8aaac97638edd18e03b41d1bc2b8755
P2860
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.